Cancer cérvico uterino estadio IIIB tratado con radioquimioterapia concomitante basada en cisplatino: Experiencia inicial Hospital Carlos Van Buren

Abstract

Objective: With a retrospective study we propose to analyze results and prognostic factors of patients with FIGO stage IIIB cervical carcinoma of the intact uterine cervix treated with cisplatin-based chemotherapy concurrently with standard radiotherapy. Methods: From September 1999 to December 2002, 48 patients with stage IIIB cervical carcinoma were treated at the department of oncology from Carlos Van Buren Hospital. The mean age was 46.7 years; 89.5% was squamous cell carcinoma. Treatment consisted of radiotherapy (external-beam radiotherapy and low dose rate brachytherapy) plus weekly cisplatin chemotherapy (40 mg/m2) for five weeks. The total dose to point A was 85 Gy. Results: 85.4% received 5 cycles. The median overall survival was 39 months with 3 year overall survival, disease-free survival and loco-regional disease-free survival of 55.6%, 53.3% and 78.6%, respectively. 12.5% had recurrence disease in pelvis and 22.9% developed metastatic disease. We did not find prognostic factors for overall survival and disease-free survival. Prognostic factors related with poor loco-regional disease-free survival were clinical tumor diameter ≥ 7 cm and patients who did not have brachytherapy. Conclusions: The treatment regimen of external pelvic irradiation, brachytherapy and concurrent weekly cisplatin in patients with stage IIIB cervical carcinomas is feasibility to do in the Chilean public health system, with good tolerance and comparable results to the international trials.